One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.3622
Abstract: Romosozumab, a humanized monoclonal antibody that binds and inhibits sclerostin, has the dual effect of increasing bone formation and decreasing bone resorption. As previously reported in the pivotal FRActure study in postmenopausal woMen with ostEoporosis… read more here.
Keywords: fracture; study; bone; fracture risk ... See more keywords
T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.3996
Abstract: In the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) clinical trial (NCT01631214), 1 year of romosozumab followed by alendronate reduced the risk of vertebral and nonvertebral fractures compared to alendronate alone… read more here.
Keywords: romosozumab; fracture; year; fracture risk ... See more keywords
Osteoporosis: Romosozumab versus teriparatide
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Rheumatology"
DOI: 10.1038/nrrheum.2017.135
Abstract: The effect of two bone-forming agents — the anti-slerostin antibody romosozumab and the recombinant PTH teriparatide — were compared in an open-label, randomized phase III study involving 436 women with postmenopausal osteoporosis who had been… read more here.
Keywords: romosozumab versus; osteoporosis romosozumab; rheumatology; romosozumab ... See more keywords
Letter to the editor: consideration on: ‘What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?’ by Reid I.R
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2023.2173737
Abstract: We read with great interest the editorial by I.R. Reid published in Expert Opinion on Drug Safety [1]. The Author addressed cardiovascular safety of romosozumab. He thoroughly discussed data from the ARCH trial [2] that… read more here.
Keywords: romosozumab; number needed; alendronate; risk ... See more keywords
Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
Sign Up to like & getrecommendations! Published in 2022 at "Women's Health"
DOI: 10.1177/17455057221125577
Abstract: Increased understanding of the Wnt signaling pathway has led to the development of romosozumab, one of the most potent osteoanabolic agents to date for osteoporosis treatment. Romosozumab is a monoclonal antibody that inhibits sclerostin, a… read more here.
Keywords: romosozumab; osteoporosis; risk; cardiovascular risk ... See more keywords
Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Pharmacy Technology"
DOI: 10.1177/8755122520967632
Abstract: Objective: To review the safety and efficacy of romosozumab (Evenity) in the treatment of osteoporosis in women. Data Sources: An English-language search of PubMed and Medline (1966 to August 2020) was conducted using the keywords… read more here.
Keywords: romosozumab novel; treatment; novel agent; romosozumab ... See more keywords
The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24087574
Abstract: Sclerostin is a bone formation inhibitor produced by osteocytes. Although sclerostin is mainly expressed in osteocytes, it was also reported in periodontal ligament (PDL) fibroblasts, which are cells that play a role in both osteogenesis… read more here.
Keywords: romosozumab; sclerostin; formation; pdl ... See more keywords